Drug Trial Radar · NCT00550862
Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC)
Last checked: Nov 19, 2026Latest source record: Feb 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
165
Actual
Start
Oct 2007
Primary completion
Aug 2009
Study completion Dec 2010
Sponsor
- Lead sponsor
- Intercept PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Oct 30, 2007
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary hypothesis is that INT-747 will cause a reduction in alkaline phosphatase levels in Primary Biliary Cirrhosis patients, over a 12 week treatment period, as compared to placebo.
Conditions
- Liver Cirrhosis, Biliary
Interventions
INT-747Drug
Once a day (QD) by mouth (PO)
Ursodeoxycholic Acid (URSO)Drug
Stable dose for at least 6 months prior to screening. Dose as prescribed by physician.
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Double-blind Phase: Percent Change From Baseline in Serum Alkaline Phosphatase (ALP)Time frame: Baseline and Up to Day 85
Locations
32 sites in 8 countries. Site status is shown where the registry gives one.
U Florida Hepatology
Gainesville, Florida
University of Miami - Center for Liver Diseases
Miami, Florida
Tufts Medical Center
Boston, Massachusetts
Henry Ford Health Center Columbus
Novi, Michigan
Mayo Clinic
Rochester, Minnesota
Saint Louis University
St Louis, Missouri
Beth Israel Medical Center
New York, New York
Mt. Sinai School of Medicine
New York, New York
Cleveland Clinic
Cleveland, Ohio
UT Southwestern Medical Center
Dallas, Texas
Baylor College of Medicine
Houston, Texas
McGuire DVAMC
Richmond, Virginia
Virginia Mason Medical Center
Seattle, Washington
Karls-Franzens University
Graz, Austria
University of Calgary
Calgary, Alberta, Canada
University of Alberta
Edmonton, Alberta, Canada
University of Manitoba
Winnipeg, Manitoba, Canada
University of Toronto Western Hospital
Toronto, Ontario, Canada
Centre de Recherche du CHUM / University of Montreal
Montreal, Quebec, Canada
Hopital de l'Hotel Dieu
Lyon, France
Johann Wolfgang Goethe University
Frankfurt, Germany
University Medical Centre Hamburg-Eppendorf
Hamburg, Germany
Medical School of Hannover
Hanover, Germany
University of Munich
Munich, Germany
AMC University of Amsterdam
Amsterdam, Netherlands
Erasmus Medical Centre
Rotterdam, Netherlands
Hospital Clinic i Provincial
Barcelona, Spain
Royal Infirmary
Edinburgh, United Kingdom
University Upon Tyne/Newcastle
Newcastle upon Tyne, United Kingdom
Queen Elizabeth Medical Center
Edgbaston, Birmingham, United Kingdom
Royal Free Hospital
Hampstead, London, United Kingdom
John Radcliffe Hospital
Headington, Oxford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.